Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Latorre

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|July 10, 2016
ReplyPierluigi Paggiaro, Manuela Latorre
Pulmonology|February 9, 2020
Is adherence to treatment influenced by the ability to use inhaled devices in patients with COPD correctly?Manuela Latorre, Giulia Parri, Pierluigi Paggiaro
Therapeutic Advances in Chronic Disease|May 26, 2021
Chronic obstructive pulmonary disease: moving from symptom relief to mortality reductionAlessandro Celi, Manuela Latorre, Pierluigi Paggiaro, et al.
Expert Opinion on Biological Therapy|April 30, 2019
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?Francesco Menzella, Manuela Latorre, Patrizia Ruggiero, et al.
Clinical and Experimental Rheumatology|September 27, 2012
Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitisDaniela Martini, Chiara Baldini, Manuela Latorre, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 28, 2018
The Severe Asthma Network in Italy: Findings and PerspectivesEnrico Heffler, Francesco Blasi, Manuela Latorre, et al.
Respiratory Medicine|November 21, 2021
Are sputum eosinophils associated with a different phenotype in COPD patients? A retrospective studyMaria Laura Bartoli, Manuela Latorre, Barbara Vagaggini, et al.
Pulmonary Pharmacology & Therapeutics|March 18, 2017
Can the response to Omalizumab be influenced by treatment duration? A real-life studyBruno Sposato, Marco Scalese, Manuela Latorre, et al.
BMC Pulmonary Medicine|December 13, 2016
High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroidsPierluigi Paggiaro, Massimo Corradi, Manuela Latorre, et al.
Mediators of Inflammation|December 13, 2018
Nasal Cytology: A Comparative Study of Two Different Techniques of Processing-Smeared versus Cytocentrifuged SlidesMaria Laura Bartoli, Lodovica Cristofani-Mencacci, Mariella Scarano, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology. in Practice|July 10, 2016
ReplyPierluigi Paggiaro, Manuela Latorre
Pulmonology|February 9, 2020
Is adherence to treatment influenced by the ability to use inhaled devices in patients with COPD correctly?Manuela Latorre, Giulia Parri, Pierluigi Paggiaro
Therapeutic Advances in Chronic Disease|May 26, 2021
Chronic obstructive pulmonary disease: moving from symptom relief to mortality reductionAlessandro Celi, Manuela Latorre, Pierluigi Paggiaro, et al.
Expert Opinion on Biological Therapy|April 30, 2019
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?Francesco Menzella, Manuela Latorre, Patrizia Ruggiero, et al.
Clinical and Experimental Rheumatology|September 27, 2012
Future prospects for salivary proteomics in rheumatology: the example of eosinophil granulomatosis with polyangiitisDaniela Martini, Chiara Baldini, Manuela Latorre, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 28, 2018
The Severe Asthma Network in Italy: Findings and PerspectivesEnrico Heffler, Francesco Blasi, Manuela Latorre, et al.
Respiratory Medicine|November 21, 2021
Are sputum eosinophils associated with a different phenotype in COPD patients? A retrospective studyMaria Laura Bartoli, Manuela Latorre, Barbara Vagaggini, et al.
Pulmonary Pharmacology & Therapeutics|March 18, 2017
Can the response to Omalizumab be influenced by treatment duration? A real-life studyBruno Sposato, Marco Scalese, Manuela Latorre, et al.
BMC Pulmonary Medicine|December 13, 2016
High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroidsPierluigi Paggiaro, Massimo Corradi, Manuela Latorre, et al.
Mediators of Inflammation|December 13, 2018
Nasal Cytology: A Comparative Study of Two Different Techniques of Processing-Smeared versus Cytocentrifuged SlidesMaria Laura Bartoli, Lodovica Cristofani-Mencacci, Mariella Scarano, et al.
Pageof 6